open access

Vol 65, No 6 (2014)
Review article
Published online: 2014-12-31
Submitted: 2014-06-10
Accepted: 2014-08-20
Get Citation

Adrenocortical cancer (ACC) — literature overview and own experience

Dorota Dworakowska*, Agata Drabarek*, Ingrid Wenzel, Anna Babińska, Renata Świątkowska-Stodulska, Krzysztof Sworczak
DOI: 10.5603/EP.2014.0069
·
Endokrynologia Polska 2014;65(6):492-512.

open access

Vol 65, No 6 (2014)
Review article
Published online: 2014-12-31
Submitted: 2014-06-10
Accepted: 2014-08-20

Abstract

Adrenocortical carcinoma (ACC) is a malignant endocrine tumour. The rarity of the disease has stymied therapeutic development. Age distribution shows two peaks: the first and fifth decades of life, with children and women more frequently affected. Although 60–70% of ACCs are biochemically found to overproduce hormones, it is not clinically apparent in many cases. If present, endocrine symptoms include signs of hypercortisolaemia, virilisation or gynaecomastia. ACC carries a poor prognosis, and a cure can be achieved only by complete surgical resection. Mitotane is used both as an adjuvant treatment and also in non-operative patients. The role of radio- and chemotherapy is still controversial. The post-operative disease free survival is low and oscillates around 30% due to high tumour recurrence rate. The diagnosis is based on tumour histological assessment with the use of the Weiss score, however urinary steroid profiling (if available) can serve to differentiate between ACC and other adrenal tumours. Conventional prognostic markers in ACC include stage and grade of disease, and, as currently reported, the presence of hypercortisolaemia. Molecular analysis has had a significant impact on the understanding of the pathogenetic mechanism of ACC development and the evaluation of prognostic and predictive markers, among which alterations of the IGF system, the Wnt pathway, p53 and molecules involved in cancer cell invasion properties and angiogenesis seem to be very promising. We here summarise our own experience related to the management of ACC and present a literature overview. We have not aimed to include a detailed summary of the molecular alterations biology described in ACC, as this has already been addressed in other papers. (Endokrynol Pol 2014; 65 (6): 492–512)

Abstract

Adrenocortical carcinoma (ACC) is a malignant endocrine tumour. The rarity of the disease has stymied therapeutic development. Age distribution shows two peaks: the first and fifth decades of life, with children and women more frequently affected. Although 60–70% of ACCs are biochemically found to overproduce hormones, it is not clinically apparent in many cases. If present, endocrine symptoms include signs of hypercortisolaemia, virilisation or gynaecomastia. ACC carries a poor prognosis, and a cure can be achieved only by complete surgical resection. Mitotane is used both as an adjuvant treatment and also in non-operative patients. The role of radio- and chemotherapy is still controversial. The post-operative disease free survival is low and oscillates around 30% due to high tumour recurrence rate. The diagnosis is based on tumour histological assessment with the use of the Weiss score, however urinary steroid profiling (if available) can serve to differentiate between ACC and other adrenal tumours. Conventional prognostic markers in ACC include stage and grade of disease, and, as currently reported, the presence of hypercortisolaemia. Molecular analysis has had a significant impact on the understanding of the pathogenetic mechanism of ACC development and the evaluation of prognostic and predictive markers, among which alterations of the IGF system, the Wnt pathway, p53 and molecules involved in cancer cell invasion properties and angiogenesis seem to be very promising. We here summarise our own experience related to the management of ACC and present a literature overview. We have not aimed to include a detailed summary of the molecular alterations biology described in ACC, as this has already been addressed in other papers. (Endokrynol Pol 2014; 65 (6): 492–512)

Get Citation

Keywords

adrenocortical cancer; surgery; mitotane; radiotherapy; cancer

About this article
Title

Adrenocortical cancer (ACC) — literature overview and own experience

Journal

Endokrynologia Polska

Issue

Vol 65, No 6 (2014)

Pages

492-512

Published online

2014-12-31

DOI

10.5603/EP.2014.0069

Bibliographic record

Endokrynologia Polska 2014;65(6):492-512.

Keywords

adrenocortical cancer
surgery
mitotane
radiotherapy
cancer

Authors

Dorota Dworakowska*
Agata Drabarek*
Ingrid Wenzel
Anna Babińska
Renata Świątkowska-Stodulska
Krzysztof Sworczak

Important: This website uses cookies.tanya dokter More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Via MedicaWydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl